Early clinical stage therapeutics company developing BRY101, a metabolic modulator engineered to increase intracellular NAD, impacting mitochondrial dysfunction, neuroinflammation and oxidative stress. BRY101 impacts multiple pathways simultaneously, breaking away from the traditional single-target drug development model. This strategy is designed to address the complex mechanisms involved in neurodegenerative and neuromuscular disorders. Bryleos: More Life While Living
| Website | http://www.bryleos.com |
| Employees | 9 (2 on RocketReach) |
| Founded | 2021 |
| Address | 207 North Boone Street Suite 15, Johnson City, Tennessee 37604, US |
| Industry | Biotechnology Research |
| Keywords | Precision Medicine, Biotechnology, Molecular Pathways, Therapeutics, Clinical Development, Drug Development, Pharmaceutical, Mitochondrial Dysfunction, Neuroinflammation, Oxidative Stress, Cellular Metabolism, Biotech, Pharma, Clinical Trials, Drug Discovery, Life Sciences, Health Tech |
| Competitors | Deloitte, Bain & Company, Marsh, Aon, Oliver Wyman, Milliman, WTW, Zywave, Rms Risk Management Inc +41 more (view full list) |
Looking for a particular Bryleos employee's phone or email?
Bryleos Questions
Wendy Komac is the CEO of Bryleos.
2 people are employed at Bryleos.
Bryleos is based in Johnson City, Tennessee.
Top Bryleos Employees
-
Wendy Komac
Chief Executive Officer at Bryleos
Johnson City, TN, US25+ -
John Pierce
Chief Operating Officer at Bryleos
Cleveland, OH, US25
Related Companies
